Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
18.18
+0.27 (1.51%)
At close: Dec 18, 2025, 4:00 PM EST
18.18
0.00 (0.00%)
After-hours: Dec 18, 2025, 4:10 PM EST
Theravance Biopharma Employees
Theravance Biopharma had 97 employees as of December 31, 2024. The number of employees decreased by 2 or -2.02% compared to the previous year.
Employees
97
Change (1Y)
-2
Growth (1Y)
-2.02%
Revenue / Employee
$828,113
Profits / Employee
$302,515
Market Cap
921.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 97 | -2 | -2.02% |
| Dec 31, 2023 | 99 | -12 | -10.81% |
| Dec 31, 2022 | 111 | -48 | -30.19% |
| Dec 31, 2021 | 159 | -200 | -55.71% |
| Dec 31, 2020 | 359 | 43 | 13.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TBPH News
- 9 days ago - Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy Transcript - Seeking Alpha
- 4 weeks ago - Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 - PRNewsWire
- 4 weeks ago - Theravance Biopharma to Participate in Upcoming Investor Conferences - PRNewsWire
- 5 weeks ago - Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 7 weeks ago - Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System - PRNewsWire
- 7 weeks ago - Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 - PRNewsWire
- 2 months ago - Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy - Business Wire